文献速递白血病淋巴瘤

Cortactin作为Lyn底物是慢性淋巴细胞白血病细胞中BCR与CXCR4信号通路交汇处的检查点分子

Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
PubMed 文献 · Br J Haematol · 2017-04-17

本文旨在明确Cortactin(CTTN)在慢性淋巴细胞白血病(CLL)患者中的功能作用。研究发现Cortactin在外周血和淋巴结中表达不一,其表达与基质金属蛋白酶9(MMP-9)释放及肿瘤细胞运动相关;siRNA敲低Cortactin可减少MMP-9释放并降低白血病B细胞迁移能力,Src激酶抑制剂PP2降低Cortactin磷酸化及MMP-9释放,伊布替尼治疗后在体内外均检测到Cortactin表达和磷酸化降低。结果提示Cortactin是CLL中BCR与CXCR4信号通路之间的检查点分子。

要点

  • Cortactin在CLL患者外周血和淋巴结中表达不一,与MMP-9释放及肿瘤细胞运动相关。
  • siRNA敲低Cortactin可减少MMP-9释放并降低白血病B细胞体外迁移能力。
  • 伊布替尼治疗后在体内外均检测到Cortactin表达和磷酸化降低。

核心结论

  • Cortactin是CLL中BCR与CXCR4信号通路之间的检查点分子。

研究设计与样本

  • 本研究旨在明确Cortactin在CLL患者中的功能作用,检测了患者外周血和淋巴结中的表达,并进行了siRNA敲低、Src激酶抑制剂PP2及伊布替尼处理的体外和体内实验。

主要发现

  • Cortactin在CLL患者外周血和淋巴结中表达不一,其表达与MMP-9释放及肿瘤细胞运动相关。
  • siRNA敲低Cortactin后,MMP-9释放减少,白血病B细胞体外迁移能力下降,包括趋化刺激后。
  • Src激酶抑制剂PP2降低Cortactin磷酸化,培养液中MMP-9释放随之减少。
  • CXCL12触发后,与未敲低Cortactin的对照实验相比,观察到迁移受损。
  • 伊布替尼(Btk抑制剂)治疗后在体内和体外均检测到Cortactin表达和磷酸化降低。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cortactin (CTTN) is a substrate of the Src kinase Lyn that is known to play an actin cytoskeletal regulatory role involved in cell migration and cancer progression following its phosphorylation at Y421. We recently demonstrated that Cortactin is overexpressed in patients with chronic lymphocytic leukaemia (CLL). This work was aimed at defining the functional role of Cortactin in these patients. We found that Cortactin is variably expressed in CLL patients both in the peripheral blood and lymph nodes and that its expression correlates with the release of matrix metalloproteinase 9 (MMP-9) and the motility of neoplastic cells. Cortactin knockdown, by siRNA, induced a reduction in MMP-9 release as well as a decrease of migration capability of leukaemic B cells in vitro, also after chemotactic stimulus. Furthermore, Cortactin phosphorylation was lowered by the Src kinase-inhibitor PP2 with a consequent decrease of MMP-9 release in culture medium. An impaired migration, as compared to control experiments without Cortactin knockdown, was observed following CXCL12 triggering. Reduced Cortactin expression and phosphorylation were also detected both in vivo and in vitro after treatment with Ibrutinib, a Btk inhibitor. Our results highlight the role of Cortactin in CLL as a check-point molecule between the BCR and CXCR4 signalling pathways.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Martini V, Gattazzo C, Frezzato F, et al. Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. Br J Haematol. 2017. PMID: 28419476. doi:10.1111/bjh.14642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。